Phase III success for Skyrizi in ulcerative colitis

A positive Phase III result in ulcerative colitis will support the ongoing commercial success of AbbVie’s (NYSE: ABBV) JAK blocker Skyrizi (risankizumab).

The biologic’s strong performance in ulcerative colitis (UC) comes less than a year after the interleukin (IL)-23 inhibitor won US approval in Crohn’s disease, a more common form of inflammatory bowel disease (IBD).

Developed in collaboration with Germany’s Boehringer Ingelheim, Skyrizi would compete with existing biologics Stelara (ustekinumab), from Johnson & Johnson (NYSE: JNJ), and Entyvio (vedolizumab), from Takeda Pharmaceutical (TYO: 4502), were it to be approved in UC.